Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 351 matching trials from the live ClinicalTrials.gov search.
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Terminated Phase 3 Interventional Results available

The Everolimus-Transplant Exit Strategy Trial (E-TEST)

NCT01636466
Conditions
Kidney Failure, Chronic
Interventions
Everolimus
Drug
Lead sponsor
Ashtar Chami
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Renal Failure, Hemodialysis
Interventions
GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface, Percutaneous Transluminal Angioplasty
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 26 more
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Transform Kidney Care and Improve Pursuit of Transplant

NCT07794631
Conditions
Kidney Disease, Kidney Transplant, Deceased Donor Kidney Transplant, Living Donor Kidney Transplantation, Chronic Kidney Disease (Stages 3b-5)
Interventions
Digital Health Integration, Training for Early Transplant Access and Support, Kidney Health Mobile Health (mHealth) Application
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pasadena, California
Conditions
Chronic Kidney Failure, HIV Infection
Interventions
immunosuppressive regimen designed to complement HAART
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Kidney Transplantation
Interventions
Lumason Contrast-Enhanced Ultrasound
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Kidney Failure, Chronic, Multiple Myeloma
Interventions
Combined bone marrow and kidney transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

NCT05490511
Conditions
CBD, Transplant Complication, Kidney Disease, Chronic
Interventions
Tacrolimus single dose, Epidiolex single dose, Epidiolex steady-state and tacrolimus single dose
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
ESRD
Interventions
Hispanic Kidney Transplant Program (HKTP)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
11,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Denver, Colorado • Dallas, Texas + 1 more
Recruiting No phase listed Observational Accepts healthy volunteers

International (Pediatric) Peritoneal Biobank

NCT01893710
Conditions
Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy
Interventions
biopsy sampling
Procedure
Lead sponsor
Heidelberg University
Other
Eligibility
1 Day to 90 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Kansas City, Missouri • Narberth, Pennsylvania
Conditions
Liver Failure, Renal Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions
TAP, TAU
Behavioral · Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
New York, New York • Richmond, Virginia
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Conditions
ESRD
Interventions
Immune Tolerance
Drug
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
glecaprevir/pibrentasvir treatment
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Multiple Myeloma
Interventions
Bortezomib, Isatuximab, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study

NCT00951977
Conditions
End Stage Renal Disease, Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
7,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Completed No phase listed Observational

Live Kidney Donor Study

NCT00608283
Conditions
Kidney Transplantation, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Conditions
Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
Interventions
TNX-1500, Kidney Transplant
Drug · Procedure
Lead sponsor
Ayman Al Jurdi, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts